Trial · NCT03011684
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
NCT03011684, Phase 3, Recruiting, University of California, San Francisco
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial. Trials, record NCT03011684. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03011684
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
- NCT number
- NCT03011684
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 309 participants, estimated
- Lead sponsor
- University of California, San Francisco
- Conditions
- Infertility
- Interventions
- Tamoxifen, Letrozole
- First posted
- 2017-01-05
- Last updated
- 2026-06-04
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mature Oocyte Yield | Up to 2 weeks | To determine if the assigned stimulation regimen will result in a difference in mature (meiosis II) oocyte yield in patients with breast cancer who undergo ovarian stimulation for fertility preservation. An Effect Size of 3 mature oocytes, based on clinically significant difference of 2 embryos to transfer. An average of 2 embryos are transferred per freeze-thaw cycle. If \~75% of mature oocytes will become embryos that can be frozen, then 3 mature oocytes should yield \~2 embryos for transfer. This effect size would effectively mean an additional event of embryos transferred. |
| Secondary | Compare change in estrogen levels during the ovarian stimulation cycle | Up to 2 weeks | Estrogen level data will be collected at baseline and after completion of the stimulation cycle |
| Secondary | Compare change in progesterone levels during the ovarian stimulation cycle | Up to 2 weeks | Progesterone level data will be collected at baseline and after completion of the stimulation cycle |
| Secondary | Compare change in androgen levels during the ovarian stimulation cycle | Up to 2 weeks | Androgen level data will be collected at baseline and after completion of the stimulation cycle |
| Secondary | Compare change in estrogen in follicular fluid | Up to 2 weeks | Estrogen levels in follicular fluid will be collected at baseline and after completion of the stimulation cycle |
| Secondary | Compare change in letrozole in follicular fluid | Up to 2 weeks | Letrozole levels in follicular fluid will be collected at baseline and after completion of the stimulation cycle |
| Secondary | Compare change in tamoxifen in follicular fluid | Up to 2 weeks | Tamoxifen levels in follicular fluid will be collected at baseline and after completion of the stimulation cycle |
| Secondary | Compare duration of stimulation (days) and total gonadotropin dose | Up to 2 weeks | The duration of stimulation in days will be compared to total gonadotropin dose across all groups. |
| Secondary | Number if competent oocytes on day 3 of embryo culture | Up to 2 weeks | To assess embryo quality, if applicable, on day 3 of embryo culture, a measure of the developmental competence of the oocytes. |
| Secondary | Number if competent oocytes on day 5 of embryo culture | Up to 2 weeks | To assess embryo quality, if applicable, on day 5 of embryo culture, a measure of the developmental competence of the oocytes. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34312774 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03011684
GET https://conductscience.org/api/trials/v1/NCT03011684/registered